Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
BJU Int ; 131(4): 471-476, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36285629

RESUMEN

OBJECTIVES: To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy. PATIENTS AND METHODS: Patients undergoing antegrade administration of mitomycin gel via PCNT were retrospectively included for analysis from four tertiary referral centres between 2020 and 2022. The primary outcome was safety profile, as graded by Common Terminology Criteria for Adverse Events (v5.0). Post-therapy disease burden was assessed by primary disease evaluation (PDE) via ureteroscopy. RESULTS: Thirty-two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0 months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow-up and there were no treatment-related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow-up of 13.0 months post induction. CONCLUSIONS: Administration of mitomycin gel via a PCNT offers a low rate of ureteric stenosis, demonstrates a favourable safety profile, and is administered without general anaesthesia.


Asunto(s)
Carcinoma de Células Transicionales , Nefrostomía Percutánea , Neoplasias Ureterales , Neoplasias de la Vejiga Urinaria , Humanos , Carcinoma de Células Transicionales/tratamiento farmacológico , Mitomicina , Estudios Retrospectivos , Constricción Patológica , Neoplasias Ureterales/tratamiento farmacológico
2.
Case Rep Anesthesiol ; 2021: 1150394, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34350037

RESUMEN

Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of disease and has rarely been reported in pregnancy. We present the case of a 22-year-old woman with antisynthetase syndrome and severe restrictive pulmonary disease who experienced a successful pregnancy and delivery. We discuss anesthetic considerations and highlight the importance of a multidisciplinary team approach in caring for parturients with multifactorial medical conditions.

3.
Pain Pract ; 21(3): 299-307, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33058387

RESUMEN

BACKGROUND AND OBJECTIVES: Optimizing perioperative analgesia for patients undergoing major lower-extremity amputation remains a considerable challenge. The utility of liposomal bupivacaine as a component of peripheral nerve blockade for lower-extremity amputation is unknown. METHODS: We conducted an observational study comparing three different perioperative analgesic techniques for adults undergoing major lower-extremity amputation under general anesthesia between 2012 and 2017 at an academic medical center: (1) no regional anesthesia, (2) peripheral nerve blockade with standard bupivacaine, and (3) peripheral nerve blockade with a mixture of standard and liposomal bupivacaine. The primary outcome of cumulative opioid oral morphine milligram equivalent utilization in the first 72 hours postoperatively was compared across groups utilizing multivariable linear regression. RESULTS: A total of 631 unique anesthetics were included for 578 unique patients, including 416 (66%) without regional anesthesia, 131 (21%) with peripheral nerve blockade with a mixture of standard and liposomal bupivacaine, and 84 (13%) with peripheral nerve blockade with standard bupivacaine alone. Cumulative morphine equivalents were lower in those receiving peripheral nerve blockade with combined standard and liposomal bupivacaine compared with those not receiving regional anesthesia (multiplicative increase 0.67; 95% CI 0.50 to 0.90; P = 0.007). There were no significant differences in opioid utilization between peripheral nerve blockade groups (P = 0.59). CONCLUSIONS: Peripheral nerve blockade is associated with reduced opioid requirements after lower-extremity amputation compared with general anesthesia alone. However, the incorporation of liposomal bupivacaine is not significantly different to blockade employing only standard bupivacaine.


Asunto(s)
Amputación Quirúrgica/efectos adversos , Bupivacaína/administración & dosificación , Extremidad Inferior/cirugía , Bloqueo Nervioso/métodos , Dolor Postoperatorio/tratamiento farmacológico , Anciano , Amputación Quirúrgica/métodos , Analgésicos/administración & dosificación , Analgésicos Opioides/administración & dosificación , Anestesia de Conducción/métodos , Anestesia de Conducción/normas , Anestésicos Locales/administración & dosificación , Estudios de Cohortes , Quimioterapia Combinada , Femenino , Humanos , Inyecciones , Liposomas , Extremidad Inferior/inervación , Masculino , Persona de Mediana Edad , Morfina/administración & dosificación , Bloqueo Nervioso/normas , Nervios Periféricos/efectos de los fármacos , Estados Unidos
4.
Pediatr Dermatol ; 33(2): e121-2, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26763866

RESUMEN

Heterochromia of the hair involves the presence of two distinctive colors of scalp hair in one individual. We report the case of a 4-year-old girl with reddish streaks of scalp hair, heterochromia of the eyelashes, and cutaneous hypopigmentation following the lines of Blaschko.


Asunto(s)
Pestañas/anomalías , Color del Cabello , Cabello/anomalías , Trastornos de la Pigmentación/diagnóstico , Preescolar , Femenino , Humanos
5.
Psychosomatics ; 56(6): 609-14, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26497617

RESUMEN

BACKGROUND: Descriptions of malingering imposed on another, in which an individual induces or exaggerates symptoms in another for secondary gain (including financial benefit or access to medications), are remarkably scant in the current literature. We summarize reported cases of malingering imposed on another in order to underscore its relevance to practicing physicians. OBJECTIVE: We sought to review the available literature describing the creation or exaggeration of symptoms of illness, motivated by secondary gain, in another vulnerable individual. METHOD: A search of the literature using PubMed was undertaken searching the terms "malingering," "by proxy," and "imposed on another." RESULTS: Malingering imposed on another may be under-reported in the professional literature. Maintaining awareness that caregivers may misrepresent or embellish the symptoms of the identified patient for their own gain is an important consideration to forestall unnecessary testing, hospital admission, and exposure to adverse effects of treatments.


Asunto(s)
Simulación de Enfermedad/diagnóstico , Síndrome de Munchausen Causado por Tercero/diagnóstico , Cuidadores , Humanos
6.
Pain ; 149(1): 152-159, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20171009

RESUMEN

Plasticity in the spinal dorsal horn may contribute to the development of pain following peripheral nerve injury. Shank proteins are a constituent family of the post-synaptic density (PSD), and they may play a role in synaptic plasticity through activity-dependent synaptic remodeling and growth. In this study we examined the early consequences of the loose ligation of the sciatic nerve on Shank1 protein and message levels in the PSD of spinal dorsal horn neurons. Four hours after sciatic ligation, the protein levels of Shank1 increased in the ipsilateral PSD of ligated animals. In contrast, no changes were detected in the contralateral PSD of these ligated animals, or either the ipsilateral or contralateral PSD of sham-operated animals. Shank1 was linked to the PSD marker protein PSD-95 and the NR2B subunit of NMDA receptors. The ligated animals also exhibited two early signs of pain behavior, a shift in weight distribution and thermal hyperalgesia. There was no overall change in Shank1 message in either ligated or sham-operated animals. The accumulation of Shank1 in the PSD was abolished by intrathecal pre-treatment with anisomycin or Shank1 siRNA, but not with non-target siRNA. The same pre-treatment prevented both the early signs of pain behavior. Intrathecal pre-treatment with either MK-801 or U0126 similarly prevented the Shank1 accumulation and alleviated both the behavioral signs of pain. The early accumulation of Shank1 in the PSD of dorsal horn neurons may be a necessary step in the injury-associated plasticity that in time leads to the development of persistent pain.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Hiperalgesia/fisiopatología , Células del Asta Posterior/metabolismo , Neuropatía Ciática/fisiopatología , Potenciales Sinápticos , Animales , Hiperalgesia/etiología , Hiperalgesia/patología , Ligadura , Masculino , Proteínas del Tejido Nervioso , Ratas , Ratas Sprague-Dawley , Neuropatía Ciática/complicaciones , Neuropatía Ciática/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...